Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mena Abdelmalak

Pain Medicine College Station, TX Medical Doctor

NPI 1073044590 CMS profile 11300404

800 Scott And White Dr, College Station, TX 77845

Open in the dashboard

General payments

$12,128

75 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mena Abdelmalak of College Station, TX is reported in the CMS Open Payments database as having received $12,128 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $63 3
2024 General $446 4
2023 General $2,811 19
2022 General $6,474 39
2021 General $2,334 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mena Abdelmalak
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Mena Abdelmalak were reported at $63. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Mena Abdelmalak Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $0 $284 $80–$910 $114
2021 $2,334 $399 $112–$1,219 $132
2022 $6,474 $455 $137–$1,484 $149
2023 $2,811 $484 $128–$1,495 $160
2024 $446 $498 $131–$1,540 $164
2025 $63 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $5,501 27 payments
  2. Abbott Laboratories $4,380 22 payments
  3. Medtronic, Inc. $1,099 11 payments
  4. Nevro Corp. $380 5 payments
  5. Saluda Medical Americas, Inc. $246 3 payments
  6. MML US, Inc. $166 2 payments
  7. Nalu Medical, Inc. $147 1 payment
  8. Vertos Medical, Inc. $124 1 payment
  9. SPR Therapeutics, Inc $66 2 payments
  10. Averitas Pharma Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $7,634 25 payments
  2. Food and Beverage $4,493 50 payments
Products named General payments · program years 2021–2025
  1. PROCLAIM Neuromodulation $1,959 7 payments
  2. Superion $1,886 7 payments
  3. PROCLAIM Neuromodulation $1,227 10 payments
  4. Superion Indirect Decompression System $1,122 6 payments
  5. PRODIGY $1,114 4 payments
  6. INTELLIS ADAPTIVESTIM $649 7 payments
  7. Senza $380 5 payments
  8. Evoke SCS $246 3 payments
  9. General - Pain Management $220 2 payments
  10. McGRATH $174 1 payment
  11. Other $917 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,004

Median for Anesthesiology: 322

Drug cost

$11,910

Median for Anesthesiology: $8,738

Branded share of claims

6.1%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 375 $3,482
Pregabalin Generic 179 $2,733
Lidocaine Generic 19 $2,022
Duloxetine Hcl Generic 90 $970
Celecoxib Generic 23 $519
Diclofenac Sodium Generic 32 $505
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 20 $377
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 41 $373
Tizanidine Hcl Generic 73 $364
Baclofen Generic 40 $229

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$58,316

Of which drugs: $135

Medicare patients

153

Average age 73

Services billed

1,607

85 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 47%
Chronic kidney disease 31%
Depression 31%
Ischemic heart disease 24%
COPD 21%
Cancer 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 19 841 $85

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record